Catalyst Pharma & SERB SA v. Inventia Healthcare: Voluntarily Dismissed in 18 Days
Catalyst Pharmaceuticals and SERB SA filed a six-patent infringement action in Delaware against Inventia Healthcare over Amifampridine Tablets 10mg. The plaintiffs voluntarily dismissed all claims without prejudice just 18 days after filing, before the defendant had entered any appearance of record.
Six-patent Amifampridine action dropped in under three weeks
On 20 November 2023, Catalyst Pharmaceuticals, Inc. and SERB SA filed suit in the Delaware District Court against Inventia Healthcare Limited, asserting six U.S. patents — US11268128B2, US11274332B2, US11274331B2, US10626088B2, US10793893B2, and US11060128B2 — covering Amifampridine Tablets 10mg, a treatment associated with Lambert-Eaton Myasthenic Syndrome. Plaintiffs were represented by Gibbons PC; no defendant agent or law firm appears in the available record.
The recorded Basis of Termination is Voluntary dismissal. The docket order states that the plaintiffs, pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i), voluntarily dismissed all claims asserted against the defendant without prejudice. The specific terms underlying the dismissal are not disclosed in the available record.
The 18-day duration — from filing to dismissal — is exceptionally short, even by the standards of ANDA-related pharmaceutical patent litigation. A Rule 41(a)(1)(A)(i) dismissal is filed unilaterally by the plaintiff before the defendant has served an answer or a motion for summary judgment, which is consistent with the absence of any defendant filing in the record. What, if anything, was agreed or communicated between the parties prior to this dismissal is not disclosed in the available public record.
See Complete Case & Patent Analysis →Filing to Voluntary dismissal in 18 days
From filing to voluntary dismissal — exceptionally short for a pharmaceutical patent case
US11268128B2 and five further patents — Amifampridine Tablets 10mg
Any pharmaceutical manufacturer, generic drug company, or ANDA filer with Amifampridine Tablets 10mg in development or commercialisation should treat this six-patent portfolio as an active enforcement risk. The without-prejudice dismissal against Inventia confirms that the patent holders are willing to litigate and have preserved all rights. A comprehensive FTO is material before progressing any Amifampridine product toward ANDA submission or US market entry.
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) — the unilateral plaintiff mechanism available before any defendant answer is filed — and expressly specifies 'without prejudice.' This means the proceeding ends without any adjudication of infringement, validity, or claim scope. The six asserted patents are unaffected by the dismissal and remain enforceable on their face.
Voluntarily dismissed: what the Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): unilateral plaintiff dismissal before answer
Fed. R. Civ. P. 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without a court order, as of right, before the defendant has served an answer or a motion for summary judgment. Because no defendant filings appear in the record here, this right was available to the plaintiffs. The dismissal is self-executing upon filing of the notice.
No court order requiredDismissed without prejudice — but public record is silent on why
The notice expressly states 'without prejudice,' meaning the plaintiffs are not barred from refiling the same claims against Inventia on the same six patents. Whether the parties reached any collateral understanding is not disclosed in the available public record. The distinction matters: a with-prejudice dismissal would extinguish the claims permanently; without prejudice preserves the plaintiffs' option to refile.
Refiling remains possibleInventia exits without a merits ruling — but exposure persists
Inventia Healthcare obtained no judgment on the merits and faces no estoppel from this proceeding. However, because the dismissal is without prejudice, the six asserted patents remain enforceable and Inventia could face a refiled action. No costs or fees ruling was entered, and the specific terms of any resolution are not disclosed in the available record.
No merits adjudicationSix patents remain live enforcement tools in Amifampridine market
The voluntary without-prejudice dismissal leaves all six asserted patents — spanning multiple application families — fully enforceable. Any manufacturer seeking to commercialise Amifampridine Tablets 10mg in the US market should treat this outcome as an open enforcement posture. The compressed 18-day timeline suggests this litigation chapter is not necessarily closed for Inventia or others in this product space.
Patents remain enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Catalyst Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Serb, SA | Company | Search in Eureka ↗ |
| Defendant | Inventia Healthcare Limited | Company | /Search in Eureka ↗ |
| Plaintiff counsel | Christopher Viceconte | Attorney | Counsel for Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Catalyst Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Jennifer Choe-Groves | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the Amifampridine and rare disease pharmaceutical IP space
Forward-looking patent and R&D intelligence derived from the Catalyst Pharma and SERB SA six-patent Amifampridine portfolio — signals for product developers and IP strategists.
Catalyst Pharma's Amifampridine filing activity across application families
Catalyst Pharmaceuticals and SERB SA have built a six-granted-patent estate across multiple application families for Amifampridine Tablets 10mg. Tracking continuation and divisional filings from the US14/128672, US15/695043, US17/009250, and US17/503xxx families will reveal whether additional protection layers are being added — a key signal for any ANDA filer or competing developer.
Multi-family patent estateAmifampridine formulation patent filing trends in the US
Amifampridine and its phosphate salt form have attracted growing patent activity around formulation stability, dosing methods, and active ingredient synthesis. Mapping filing trends across IPC classes relevant to pyridine derivative pharmaceuticals can identify where innovation is converging and where white space may exist for next-generation formulations.
Rare disease pharma IP trendsInventia Healthcare's patent and product development profile
Inventia Healthcare Limited is a named defendant in this action with no filed response in the available record. Analysing Inventia's own patent filing activity, ANDA history, and product pipeline in the rare disease and neurology pharmaceutical space can provide competitive intelligence on their development direction and defensive IP capability.
Generic pharma IP postureAdjacent R&D opportunities near Amifampridine delivery and dosing
The existing patent estate concentrates on tablet composition, phosphate salt forms, and dosing methods for Amifampridine 10mg. Adjacent white space may exist in modified-release delivery systems, paediatric formulations, or combination therapy approaches — areas that may not be blocked by the current six-patent portfolio and could offer independent development pathways.
Formulation white spaceSimilar pharmaceutical patent cases in Delaware District Court
Explore comparable Amifampridine and ANDA-related patent infringement actions filed in the Delaware District Court, including cases involving voluntary dismissal and multi-patent pharmaceutical portfolios.
What this case signals for the Amifampridine pharmaceutical IP landscape
A six-patent filing dropped in 18 days raises clear signals about enforcement posture and ANDA market dynamics for Amifampridine.
Without-prejudice dismissals are not clean exits — monitor for refiling
Plaintiffs preserving their right to refile against Inventia — or other ANDA filers — is the operative risk here. All six patents remain in force. Companies active in the Amifampridine Tablets 10mg space should monitor Catalyst and SERB SA's enforcement activity across related proceedings and ANDA dockets.
Speed of dismissal signals pre-suit resolution or strategic repositioning
An 18-day lifecycle before any defendant response is filed consistently suggests either a pre-suit resolution, a strategic decision to refile in a different venue, or a change in enforcement strategy. The public record discloses none of these; parties should treat the underlying rationale as unknown but commercially significant.
Catalyst v Inventia — key questions answered
Catalyst Pharmaceuticals and SERB SA asserted six U.S. patents: US11268128B2, US11274332B2, US11274331B2, US10626088B2, US10793893B2, and US11060128B2, all relating to Amifampridine Tablets 10mg, in the Delaware District Court action filed 20 November 2023.
The recorded Basis of Termination is Voluntary dismissal. The docket order states the plaintiffs filed a Rule 41(a)(1)(A)(i) notice voluntarily dismissing all claims without prejudice. The specific terms, if any, underlying the dismissal are not disclosed in the available public record.
A without-prejudice dismissal means the plaintiffs are not barred from refiling the same claims on the same six patents against Inventia or others. No estoppel was created and no merits ruling was entered. All six asserted patents remain enforceable and available for future assertion.
The public record does not disclose the reason for the rapid dismissal. A Rule 41(a)(1)(A)(i) dismissal is available as of right before the defendant files an answer or summary judgment motion, which is consistent with the absence of any defendant filings in this case. The underlying rationale is not disclosed in the available record.
Catalyst Pharmaceuticals, Inc. and SERB SA were represented by Gibbons PC, with Christopher Viceconte listed as plaintiff agent. No defendant law firm or agent appears in the available public record, consistent with a dismissal before any defendant response was filed.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.